Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection
- 11 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 30 (11), 6357-6368
- https://doi.org/10.1007/s00330-020-06990-8
Abstract
Objectives Recurrence rate is up to 70% at 5 years for hepatocellular carcinoma (HCC) after initial resection, but the management of recurrent HCC remains unclear. To compare the efficacy and safety of radiofrequency ablation (RFA) and repeat resection as the first-line treatment in recurrent HCC. Methods This multicenter retrospective study analyzed 290 patients who underwent RFA (n = 199) or repeat resection (n = 91) between January 2006 and December 2016 for locally recurrent HCC (≤ 5 cm) following primary resection. We compared the overall survival (OS), progression-free survival (PFS), and complications between the two treatment groups for the total cohort and the propensity score matched (PSM) cohort. Results The 1-, 3-, and 5-year OS (90.7%, 69.04%, 55.6% vs. 87.7%, 62.9%, 38.1%, p = 0.11) and PFS (56.5%, 27.9%, 14.6% vs. 50.2%, 21.9%, 19.2%, p = 0.80) were similar in the RFA group and the repeat resection group. However, RFA was superior to repeat resection in complication rate and hospital stay (p ≤ 0.001). We observed similar findings in the PSM cohort of 48 pairs of patients and when OS and PFS were measured from the time of the primary resection. The OS of the RFA group was significantly better than repeat resection group among those with 2 or 3 recurrent tumor nodules in both the total cohort (p = 0.009) and the PSM cohort (p = 0.018). Conclusion RFA has the same efficacy as repeat resection in recurrent HCC patients, but with fewer complications. RFA is more efficient and safer than repeat resection in patients with 2 or 3 recurrent tumor nodules. Key Points • Recurrence rate is up to 70% at 5 years for hepatocellular carcinoma (HCC) after initial resection. • RFA has the same efficacy as repeat resection in recurrent HCC patients, but with fewer complications. • RFA may be preferred for those with 2 or 3 recurrent HCC nodules.Funding Information
- National Natural Science Foundation of China (81570551, 81770607)
- Key Research Project of Shandong Province (2016GSF201008)
This publication has 34 references indexed in Scilit:
- First-line radiofrequency ablation with or without artificial ascites for hepatocellular carcinomas in a subcapsular location: Local control rate and risk of peritoneal seeding at long-term follow-upClinical Radiology, 2013
- Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patientsAnnals of Oncology, 2013
- Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide surveyJournal of Hepatology, 2012
- A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinomaJournal of Hepatology, 2012
- Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinomaJournal of Hepatology, 2011
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Radiofrequency Ablation of Hepatocellular Carcinoma: Can Subcapsular Tumors Be Safely Ablated?American Journal of Roentgenology, 2008
- Comparison of limited and anatomic hepatic resection for hepatocellular carcinoma with hepatitis CSurgery, 2006
- A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular CarcinomaAnnals of Surgery, 2006
- Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trialThe Lancet, 2000